Co.don

Co.don PEG

Delisted

The PEG Ratio (Price/Earnings-to-Growth) of Co.don (CNWK.DE) as of Nov 10, 2026 is -0.08.

PEG

-0.08

Last updated:

PEG Ratio (Price/Earnings-to-Growth) of Co.don is 2020 -0.08 . PEG Ratio (Price/Earnings-to-Growth) of Co.don was 2019 - . It decreases by % lower compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Co.don Stock analysis

What does Co.don do? Co.don AG is a German company specializing in regenerative medicine. The company was founded in 1993 and is headquartered in Teltow near Berlin. Co.don aims to develop innovative therapies for tissue and joint damage to enable faster recovery for patients. Co.don's business model is based on the concept of tissue engineering. The company produces autologous cell therapies based on a patient's own cells. This means that the patient's own tissue is harvested to cultivate new and healthy cells that can be implanted back into the patient's body. Co.don offers various divisions to best meet the needs of patients. One of the most well-known divisions is cartilage cell therapy, which was developed to provide patients with the opportunity to heal damaged cartilage tissue in a gentle and effective manner. Another area in which the company operates is bone cell therapy. Autologous bone cells are produced to regenerate fractured or diseased bones. The company also has a division for skin-based cell therapy, which aims to heal tissue defects and minimize scarring. Co.don also offers various products tailored to the specific needs of patients. One of the most well-known products is the "Co.don Chondrosphere®" implant, made from autologous cartilage cell tissue. This implant is used to repair cartilage damage in joints and other areas of the body. Another product offered by the company is the "Co.don ViviSpray®" bone substitute material. It is produced by mixing autologous bone cells with a carrier material to promote natural bone formation. In recent years, the company has gained increasing international recognition and is now a well-known player in the field of regenerative medicine. The company has received numerous awards and has conducted several successful clinical trials that demonstrate the effectiveness of Co.don's products. Overall, Co.don AG is a company specializing in the production of autologous cell therapies. The company offers various divisions and manufactures products tailored to the specific needs of patients. With its innovative work, Co.don has contributed to revolutionizing the way tissue and joint damage are treated. Co.don is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Co.don stock

PEG Ratio (Price/Earnings-to-Growth) of Co.don is -0.08 in 2020.

On Eulerpool you can find the complete historical development of PEG Ratio (Price/Earnings-to-Growth) Co.don since 2006 – with annual values, charts, and detailed analysis.

The PEG ratio adjusts the P/E ratio by the expected earnings growth rate. A PEG below 1 may indicate an undervalued stock relative to its growth potential.

PEG = P/E Ratio / Expected Annual EPS Growth Rate

To evaluate PEG Ratio (Price/Earnings-to-Growth)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for PEG Ratio (Price/Earnings-to-Growth).

A 'good' varies by industry and company stage. On Eulerpool, you can compare PEG Ratio (Price/Earnings-to-Growth)'s Co.don with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Co.don

All Key Metrics — Co.don